Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus standard therapy in recurrent or metastatic cervical cancer
CTR20210428Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Mar 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in cervical cancer (mCC), sponsored by Akeso, Inc.. Started Mar 2021; status: completed.
02
Drugs
cadonilimab
03
Conditions
cervical cancer (mCC)
Beyond the preview
Go deeper on CTR20210428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210428.